Effect of different molecular weight hyaluronans on osteoarthritis-related protein production in fibroblast-like synoviocytes from patients with tibia plateau fracture

J Trauma. 2010 Jan;68(1):146-52. doi: 10.1097/TA.0b013e3181a92cf8.

Abstract

Background: Preventing arthritic change in a joint with an intra-articular fracture remains a challenge, especially in weight-bearing joints. Hyaluronan (HA) has been proven to be effective in relieving joint pain and improving function in chronic osteoarthritis. However, controversy still exists about its potential use in a joint with an intra-articular fracture and about whether this effect is dependent on molecular weight. We analyzed and compared the effects of two different molecular weight HAs on six osteoarthritis-related proteins expressed in fibroblast-like synoviocytes from 12 patients with tibial plateau fracture.

Methods: The interleukin (IL)-1beta-stimulated or IL-1beta-unstimulated fibroblast-like synoviocytes were cultivated with or without treatment by two different molecular weight HAs. The production of these proteins was quantified by using commercially available sandwich enzyme-linked immunosorbent assay.

Results: The results revealed that HA with a high molecular weight is more effective in downregulating proinflammatory cytokines such as interleukin-1beta and tumor necrosis factor-alpha. Conversely, HA with a low molecular weight has greater efficacy in upregulating anticatabolic enzymes, such as tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2, and in suppressing the catabolic enzyme, matrix metalloproteinase-3, which are thought to be more chondroprotective.

Conclusions: In a knee joint with an intra-articular fracture of the tibial plateau, we posit that high molecular weight HA may have a better anti-inflammatory effect, whereas low molecular weight HA has superior efficacy for chondroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Arthroscopy
  • Cells, Cultured
  • Humans
  • Hyaluronic Acid / administration & dosage
  • Hyaluronic Acid / pharmacology*
  • Injections, Intra-Articular
  • Interleukin-1beta / metabolism
  • Interleukin-1beta / pharmacology
  • Intra-Articular Fractures / metabolism
  • Matrix Metalloproteinase 3 / metabolism
  • Middle Aged
  • Molecular Weight
  • Osteoarthritis, Knee / etiology
  • Osteoarthritis, Knee / metabolism*
  • Osteoarthritis, Knee / therapy
  • Synovial Membrane / cytology
  • Synovial Membrane / drug effects
  • Synovial Membrane / metabolism*
  • Tibial Fractures / complications
  • Tibial Fractures / metabolism*
  • Tibial Fractures / pathology
  • Tibial Meniscus Injuries
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Viscosupplements / administration & dosage
  • Viscosupplements / pharmacology*
  • Young Adult

Substances

  • Interleukin-1beta
  • Tissue Inhibitor of Metalloproteinase-1
  • Tumor Necrosis Factor-alpha
  • Viscosupplements
  • Tissue Inhibitor of Metalloproteinase-2
  • Hyaluronic Acid
  • Matrix Metalloproteinase 3